These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
353 related items for PubMed ID: 3316707
1. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, Wertz GW. J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707 [Abstract] [Full Text] [Related]
2. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. Stott EJ, Ball LA, Young KK, Furze J, Wertz GW. J Virol; 1986 Nov; 60(2):607-13. PubMed ID: 3773052 [Abstract] [Full Text] [Related]
3. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. Bembridge GP, Garcia-Beato R, López JA, Melero JA, Taylor G. J Immunol; 1998 Sep 01; 161(5):2473-80. PubMed ID: 9725246 [Abstract] [Full Text] [Related]
4. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. Vaccine; 1992 Sep 01; 10(7):475-84. PubMed ID: 1609551 [Abstract] [Full Text] [Related]
8. Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. Wertz GW, Stott EJ, Young KK, Anderson K, Ball LA. J Virol; 1987 Feb 01; 61(2):293-301. PubMed ID: 3806789 [Abstract] [Full Text] [Related]
12. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B. Vaccine; 1999 Oct 14; 18(5-6):392-7. PubMed ID: 10519927 [Abstract] [Full Text] [Related]
13. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Openshaw PJ, Clarke SL, Record FM. Int Immunol; 1992 Apr 14; 4(4):493-500. PubMed ID: 1591217 [Abstract] [Full Text] [Related]
14. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV. Phillpotts RJ, Lescott TL, Jacobs SC. Acta Virol; 2000 Oct 14; 44(5):233-9. PubMed ID: 11252667 [Abstract] [Full Text] [Related]
18. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Wyatt LS, Shors ST, Murphy BR, Moss B. Vaccine; 1996 Oct 14; 14(15):1451-8. PubMed ID: 8994321 [Abstract] [Full Text] [Related]
19. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. Taylor J, Pincus S, Tartaglia J, Richardson C, Alkhatib G, Briedis D, Appel M, Norton E, Paoletti E. J Virol; 1991 Aug 14; 65(8):4263-74. PubMed ID: 1830113 [Abstract] [Full Text] [Related]
20. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. Connors M, Collins PL, Firestone CY, Murphy BR. J Virol; 1991 Mar 14; 65(3):1634-7. PubMed ID: 1995956 [Abstract] [Full Text] [Related] Page: [Next] [New Search]